Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Progenics Pharmaceuticals, Inc.    PGNX

PROGENICS PHARMACEUTICALS, INC.

(PGNX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Regulation FD Disclosure

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 04:12pm EDT

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Regulation FD Disclosure
Item 7.01.Regulation FD Disclosure.

On February 11, 2019, Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) issued a press release announcing acquisition of the Somerset, NJ manufacturing facility for AZEDRA® (iobenguane I 131) for cash consideration of $8.0 million. AZEDRA is the first and only FDA-approved radiopharmaceutical indicated for the treatment of pheochromocytoma and paraganglioma, ultra-rare cancers. A copy of the foregoing press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits

(d)Exhibits.

PROGENICS PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex_134515.htm EXHIBIT 99.1 ex_134515.htm Exhibit 99.1       Progenics Pharmaceuticals,…
To view the full exhibit click here

About Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.

The post Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Regulation FD Disclosure appeared first on Market Exclusive.

© Market Exclusive 2019, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PROGENICS PHARMACEUTICALS,
09:06aPROGENICS PHARMACEUTICALS : Velan Sends Letter to Progenics Stockholders
BU
06:18aPROGENICS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits ..
AQ
10/21PROGENICS PHARMACEUTICALS : Sends Letter to Shareholders
AQ
10/21PROGENICS PHARMACEUTICALS : Velan Issues Presentation Outlining Nominees' Compre..
BU
10/18PROGENICS PHARMACEUTICALS INC : Change in Directors or Principal Officers (form ..
AQ
10/09Progenics Sends Letter to Shareholders
GL
10/08PROGENICS PHARMACEUTICALS : Velan Sends Letter to Progenics Pharmaceuticals Stoc..
BU
10/04WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.
PR
10/03PROGENICS INVESTOR ALERT BY THE FORM : Kahn Swick & Foti, LLC Investigates Adequ..
BU
10/03SHAREHOLDER ALERT : Ademi & O'Reilly, LLP Investigates whether Progenics Pharmac..
PR
More news
Financials (USD)
Sales 2019 33,8 M
EBIT 2019 -76,7 M
Net income 2019 -83,2 M
Finance 2019 9,00 M
Yield 2019 -
P/E ratio 2019 -5,11x
P/E ratio 2020 -8,26x
EV / Sales2019 12,7x
EV / Sales2020 7,99x
Capitalization 437 M
Chart PROGENICS PHARMACEUTICALS, INC.
Duration : Period :
Progenics Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROGENICS PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 9,38  $
Last Close Price 5,06  $
Spread / Highest target 177%
Spread / Average Target 85,3%
Spread / Lowest Target 28,5%
EPS Revisions
Managers
NameTitle
Mark Robert Baker Chief Executive Officer & Director
Peter J. Crowley Chairman
Patrick Fabbio Chief Financial Officer, Secretary & Senior VP
Syed Mahmood Vice President-Medical Affairs
Asha Das Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROGENICS PHARMACEUTICALS, INC.15.48%437
GILEAD SCIENCES3.77%82 586
VERTEX PHARMACEUTICALS6.35%47 174
REGENERON PHARMACEUTICALS-19.63%32 607
WUXI APPTEC CO., LTD.59.43%19 525
GENMAB32.04%13 439